NASA crew readies for ISS mission launch on Thursday
Astronauts Zena Cardman and Mike Fincke, Japanese Aerospace Exploration Agency specialist Kimiya Yui and Roscosmos cosmonaut Oleg Platonov will travel from Kennedy Space Center's Launch Complex 39A to the ISS while aboard the SpaceX Crew Dragon Endeavour.
Cardman is the mission's leader. The crew landed at Space Florida's Launch and Landing Facility at 1:12 EDT after leaving from Houston on Saturday morning.
"We are absolutely joyed to be here at Kennedy Space Center," Cardman said upon the crew's landing.
"This is the first moment when it's really starting to feel real," she said. "This is the beginning of a week when things will feel progressively more and more real as we approach our launch."
Mission pilot Fincke said the mission gives him another chance to fly aboard a spacecraft named Endeavour.
"One of the last times I landed at the [Florida launch and landing facility] was on space shuttle Endeavour," Fincke told media.
"Now we get to go on another endeavor - a Dragon Endeavour," he said.
The Endeavour name honors the HMS Endeavour, which British Capt. James Cook used to explore and chart the South Pacific from 1768 to 1771.
A SpaceX Falcon 9 rocket will deliver the Endeavor into low Earth orbit, which will make the Crew Dragon spacecraft the most flown among SpaceX's fleet.
Thursday's launch is scheduled at 12:09 p.m. EDT and would enable the Endeavor to dock at the ISS on Aug. 2 if the launch occurs as planned.
The four crew members will join Expedition 73, which already is at the ISS.
An Expedition 74 crew is scheduled to replace the Expedition 73 crew while the Crew 11 team is at the ISS.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
16 minutes ago
- Forbes
Don't Miss This Weekend's Sky Show — The Moon Beside A Red Giant Star
On the evening of Sunday, Aug. 3, skywatchers will be treated to a close encounter between two of the sky's brightest nighttime objects. Just after sunset, the waxing crescent moon will appear directly beneath the red supergiant star Antares, the brightest star in the constellation Scorpius. This striking pairing, part of a repeating cycle, will be easy to spot with the naked eye. Where And When To Look Look to the southwest after sunset on Aug. 3, and as twilight deepens, you'll see the moon glowing brightly, with Antares positioned just above it. The two will be close — less than a few degrees apart — and will sink slowly toward the horizon over the next couple of hours. What You'll See The pairing of Antares and a 72%-lit waxing gibbous moon will be visible from most of the world, but a clear, unobstructed view of the southwestern sky will enhance your chances of catching them before they set. Antares means means 'rival to Mars' due to its red-orange tint and the fact that Mars passes it in the night sky every few years, causing confusion. It's a massive supergiant star located about 550 light-years from Earth and shines at magnitude 1.1. The closeness of Antares and the moon is no fluke. The moon regularly passes close to a set of bright stars that lie along the ecliptic — the same path it follows across the sky each month — those stars being Antares (in Scorpius), Aldebaran (in Taurus), Regulus (in Leo), and Spica (in Virgo). Observing Tips Most people immediately think of a telescope when they think about astronomy. It's not necessary for this event. You'll see much more just by using your naked eyes. However, a pair of binoculars is always useful when stargazing, allowing you not only to zoom in — particularly on the lunar surface — but also to better see the color of stars, such as Antares. It will look red, though since it's so low, its light may be distorted by Earth's atmosphere, so could flash a variety of colors, such as yellow and white. Choose an observing location with a clear, unobstructed view to the eastern horizon, if possible, away from city lights — though light pollution makes zero difference when observing the planets, the moon and particularly bright stars. What's Next In The Night Sky August is perfect for finding Vega, the brilliant anchor of the Summer Triangle, high in the southeast after dark. Also coming up is the full sturgeon moon on Aug. 9 and the Perseid meteor shower peak — though hampered by moonlight — on the nights of Aug. 12-13. The best nights for 'shooting stars' could actually come later, around Aug. 15. There's also a close conjunction of Jupiter and Venus on Aug. 12. For exact timings, use a sunrise and sunset calculator for where you are, Stellarium Web for a sky chart and Night Sky Tonight: Visible Planets at Your Location for positions and rise/set times for planets. Wishing you clear skies and wide eyes.
Washington Post
16 minutes ago
- Washington Post
Want to keep your brain sharp as you age? Science may have a recipe.
A mix of exercise, a healthy diet, social engagement and brain games could improve cognitive capabilities in older adults at risk of cognitive decline or dementia, a clinical trial has found. The study, known as U.S. POINTER, is the largest trial to examine how healthy lifestyle behaviors can improve brain health. Its results were published in JAMA and presented at the Alzheimer's Association International Conference on Monday in Toronto.
Yahoo
an hour ago
- Yahoo
WAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ...
Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points WAVE Life Sciences Ltd (NASDAQ:WVE) has made significant progress in RNA editing, particularly with their AATD clinical program and Eli clinical program for obesity. The company has delivered positive data from their forward 53 clinical trial of N531 for DMD, showing statistically significant improvements. WVE 006, their RNA editing oligonucleotide for alpha one antitrypsin deficiency, has shown impressive durability and a favorable safety profile. The company has expanded its second cohort for the WVE 007 obesity program due to favorable safety and robust active reduction. WAVE Life Sciences Ltd (NASDAQ:WVE) has a strong cash position, with $208.5 million in cash and cash equivalents, expected to fund operations into 2027. Negative Points The company's revenue for the second quarter of 2025 decreased to $8.7 million from $19.7 million in the prior year quarter. Research and development expenses increased to $43.5 million, driven by spending in the inhibie program and RNA editing programs. General and administrative expenses rose to $18 million, primarily due to share-based compensation and other external expenses. The net loss for the second quarter of 2025 was $50.5 million, compared to a net loss of $32.9 million in the prior year quarter. There is uncertainty regarding the potential for future milestones and payments under the GSK collaboration, which are not included in the cash runway. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with WVE. Q: For the inhibitE program, can you elaborate on your reasons for expanding cohort 2 over advancing to cohort 3 sooner? If the cohort 2 dose was well tolerated, why not just advance to cohort 3 versus expanding cohort 2? A: We didn't wait to start cohort 3; we're already dosing the 400 mg cohort. The focus on cohort 2 is due to its alignment with our DIO weight loss data and active and knee reduction modeling. Cohort 2 was modeled to align with weight loss similar to semaglutide based on the DIO model. We are encouraged by the clinical translation and are optimistic about the upcoming data readout. Q: Regarding the 006 AGD data readout, what is your guidance on the different expectations from the single-dose to multi-dose data readout? A: We expect larger liver concentration and exposure with the 200 mg multi-dose compared to the 400 mg single dose. We are encouraged by the M protein and total protein levels from the single dose and expect to see more with multi-dosing. The combination of M and total protein will provide good insights, similar to the early single-dose data. Q: On the DMD program, there were updates at the FDA level this morning. Would that affect your approach or strategy with regards to your DMD program? A: Our program goes to Cedar, which has a new division director. This division established the threshold for accelerated approvals for exon-skipping therapies. We are watching the agency's discussions, but there is nothing imminent suggesting changes to our strategy. Q: Can you discuss the extent to which you've focused on optimizing 006 so that it's competitive with others developing RNA editing therapeutics for AATD? A: We've developed 006 to have substantial editing properties that translate from pre-clinical to clinical data. Our optimized chemistry, specifically for Adar editing, and the use of Galnek for efficient delivery, differentiate our approach. This allows for subcutaneous administration and high hepatocyte uptake, distinguishing our program as best in class. Q: Regarding the ATD program, what do you believe the target conversion rate from Z to M should be? Are you looking for a near-complete conversion, or is there an acceptable amount of residual Z protein? A: The goal is to convert ZZ patients to MZ phenotype, providing sufficient protection against hepatic and lung disease. We achieved over 60% edited M protein versus Z with a single dose, which is encouraging. The target is to reach a 50% correction, aligning with the desired MZ phenotype. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
